Contact
searchSearch
HMP Global
Login

Acute Myeloid Leukemia Excellence Forum

Acute Myeloid Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Ziftomenib Plus Standard Induction Therapy Demonstrates Meaningful Clinical Activity for Patients With AML: KOMET-007
08/25/2025
Amer Zeidan, MBBS
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer Zeidan, MBBS, MHS, shared results from the KOMET-007 trial which evaluated the efficacy of ziftomenib combined with standard induction therapy for patients with newly diagnosed acute myeloid leukemia.
At the EHA 2025 Congress, Amer...
08/25/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Naval Daver, MD
Conference Coverage
Challenges of Applying MRD Decision-Making to Determine Transplant Among Patients With AML
08/05/2025
Naval G. Daver
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Naval Daver, MD, debates against minimal residual disease negativity as the predominate determining factor for transplant eligibility among patients with acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology
Aaron Goldberg, MD, PhD
Conference Coverage
Optimizing Targeted and Genetic Therapeutic Strategies for Patients With R/R Acute Myeloid Leukemia
08/05/2025
At the 2025 Great Debates in Hematologic Malignancies meeting, Aaron Goldberg, MD, PhD, discussed evolving treatment strategies and therapies for patients with relapsed/ refractory acute myeloid leukemia.
At the 2025 Great Debates in Hematologic Malignancies meeting, Aaron Goldberg, MD, PhD, discussed evolving treatment strategies and therapies for patients with relapsed/ refractory acute myeloid leukemia.
At the 2025 Great Debates in...
08/05/2025
Oncology
Andrew Artz, MD, MS
Conference Coverage
Benefits of Utilizing MRD Negativity to Determine Transplant Eligibility for Patients With AML
08/05/2025
Andrew Artz, MD, MS, participated in a debate arguing for the benefits of utilizing minimal residual disease negativity as the primary marker for transplantation eligibility among patients with acute myeloid leukemia at the 2025 Great Debates...
Andrew Artz, MD, MS, participated in a debate arguing for the benefits of utilizing minimal residual disease negativity as the primary marker for transplantation eligibility among patients with acute myeloid leukemia at the 2025 Great Debates...
Andrew Artz, MD, MS,...
08/05/2025
Oncology
Sangeetha Venugopal, MD
Videos
Utilizing Menin Inhibitor Therapy for Patients With Relapsed Acute Myeloid Leukemia
02/08/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia &...
02/08/2025
Oncology
Areej El-Jawahri, MD, Massachusetts General Hospital
Conference Coverage
Palliative Care vs Standard of Care in Discussion of End-of-Life Care Preferences for Patients With AML and MDS
06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses...
06/01/2024
Oncology
Jessica Altman, MD
Conference Coverage
Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy
04/09/2024

Featuring Jessica Altman, MD

Featuring Jessica Altman, MD
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...
During the 2024 Great Debates &...
04/09/2024
Oncology
Talha Badar, MD
Conference Coverage
Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML
01/03/2024
Talha Badar, MD
At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.
At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.
At the 65th ASH Annual Meeting,...
01/03/2024
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use